Cargando…

Monitoring of different factor VIII replacement products using a factor VIII one‐stage clotting assay on cobas t 511/711 analysers

INTRODUCTION: Recombinant coagulation factor VIII (FVIII) products are the standard of care for patients with haemophilia A. The development of modified FVIII products has provided benefit for patients but presented challenges for monitoring FVIII activity. AIM: This single‐centre study evaluated th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ketteler, Carolin, Hoffmann, Ingrid, Davidson, Simon, Tiede, Andreas, Richter, Nina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291471/ https://www.ncbi.nlm.nih.gov/pubmed/34590394 http://dx.doi.org/10.1111/hae.14416

Ejemplares similares

Impact of different factor VIII inhibitor kinetic profiles on the inhibitor titer quantification using the modified Nijmegen–Bethesda assay
por: Ketteler, Carolin, et al.
Publicado: (2022)

System performance evaluation of the cobas t 711 and cobas t 511 coagulation analyzers in routine laboratory settings
por: Kitchen, Steve, et al.
Publicado: (2020)

Clot stability as a determinant of effective factor VIII replacement in hemophilia A
por: Leong, Lilley, et al.
Publicado: (2017)

Blood Clotting Factor VIII: From Evolution to Therapy
por: Orlova, N. A., et al.
Publicado: (2013)

The Evaluation of Clot Waveform Analyses for Assessing Hypercoagulability in Patients Treated with Factor VIII Concentrate
por: Matsumoto, Takeshi, et al.
Publicado: (2023)

Performance of 6 routine coagulation assays on the new Roche Cobas t711 analyzer
por: Oostendorp, Marlies, et al.
Publicado: (2019)

Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII
por: Demers, Melanie, et al.
Publicado: (2022)

Neutrophil-to-lymphocyte ratio, Factor VIII and Antithrombin III: inflammatory-clotting biomarkers in glioma
por: Koudriavtseva, Tatiana, et al.
Publicado: (2021)

FACTOR VIII COAGULANT ACTIVITY AND FACTOR VIII-LIKE ANTIGEN: INDEPENDENT MOLECULAR ENTITIES
por: Zimmerman, Theodore S., et al.
Publicado: (1973)

Evaluation of Global Hemostatic Assays in Response to Factor VIII Inhibitors
por: Chen, Ping, et al.
Publicado: (2019)

Repression of Factor VIII Inhibitor Development with Apoptotic Factor VIII-expressing Embryonic Stem Cells
por: Sakurai, Yoshihiko, et al.
Publicado: (2013)

Factor VIII antibody immune complexes modulate the humoral response to factor VIII in an epitope-dependent manner
por: Batsuli, Glaivy, et al.
Publicado: (2023)

Platelet Function and Factor VIII in Uremia(*)
por: Park, Hee Sook, et al.
Publicado: (1987)

Tolerating Factor VIII: Recent Progress
por: Lacroix-Desmazes, Sebastien, et al.
Publicado: (2020)

Factor VIII companion diagnostic for haemophilia
por: Hu, Chunxiao, et al.
Publicado: (2022)

Lack of recombinant factor VIII B-domain induces phospholipid vesicle aggregation: implications for the immunogenicity of factor VIII
por: Grushin, K, et al.
Publicado: (2014)

Binding of Factor VIII to Lipid Nanodiscs Increases its Clotting Function in a Mouse Model of Hemophilia A
por: Csencsits-Smith, Keri, et al.
Publicado: (2015)

Natural and engineered mediators of desiccation tolerance stabilize Human Blood Clotting Factor VIII in a dry state
por: Packebush, Maxwell H., et al.
Publicado: (2023)

Global hemostatic assay of different target procoagulant activities of factor VIII and factor IX
por: Yoo, Ki-Young, et al.
Publicado: (2018)

Cogne VIII
por: CERN. Geneva. SPS-LEAR Experiments Committee
Publicado: (1995)

Enrique VIII
por: Bowle, John
Publicado: (1970)

Enrique VIII
por: Erlanger, Philippe, 1903-1987

Hæmatology—VIII
Publicado: (1910)

Modified Factor VIII and Factor IX recombinant products
por: Santagostino, Elena, et al.
Publicado: (2018)

Acquired Factor VIII Inhibitors: Three Cases
por: Kyaw, Tay Za, et al.
Publicado: (2013)

Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies
por: Scott, David W., et al.
Publicado: (2020)

Utilization of Emicizumab in Acquired Factor VIII Deficiency
por: Hess, Kevin J., et al.
Publicado: (2020)

Factor VIII/V C-domain swaps reveal discrete C-domain roles in factor VIII function and intracellular trafficking
por: Ebberink, Eduard H.T.M., et al.
Publicado: (2017)

Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy
por: Meeks, Shannon L., et al.
Publicado: (2020)

Area under the curve: Comparing the value of factor VIII replacement therapies in haemophilia A
por: Persson, Sofie, et al.
Publicado: (2022)

“Antihemophilic factor is not the only answer for all factor VIII deficiencies.” Case report of odontogenic infection in a patient with hemophilia A, complicated by factor VIII inhibitors, and managed by transfusion of antihemophilic factor and factor VIII inhibitor bypass activity
por: Sudheesh, K. M., et al.
Publicado: (2016)

King Henry VIII /
por: Shakespeare, William, 1564-1616
Publicado: (1968)

Enlargements of the Spleen—VIII
Publicado: (1908)

Enlargements of the Liver.—VIII
Publicado: (1910)

Nature Notes—VIII
Publicado: (1910)

Chapter VIII. Of Tokens
Publicado: (1894)

von Willebrand factor modulates immune complexes and the recall response against factor VIII in a murine hemophilia A model
por: Oleshko, Olga, et al.
Publicado: (2023)

Subcellular platelet factor VIII antigen and von Willebrand factor
Publicado: (1975)

Situations, VIII : Autour de 68
por: Sartre, Jean-Paul, 1905-1980
Publicado: (1972)

Factor VIII haplotypes frequencies in Tunisian hemophiliacs A
por: Elmahmoudi, Hejer, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_jbdnqfpb1c51o6ee7m6as46oes